Drug Patents owned by Pf Prism Cv
1. Drug name - BOSULIF
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE42376 | PF PRISM CV | Substituted 3-cyanoquinolines |
Apr, 2024
(1 year, 6 months from now) | |
| US7767678 | PF PRISM CV | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
Nov, 2026
(4 years from now) | |
| CN101248047A | PF PRISM CV | Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl) Propoxy]-3-Quinolinecarbonitrile And Methods Of Preparing The Same |
Jan, 2010
(12 years ago) | |
| EP1902029B1 | PF PRISM CV | Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same |
Jun, 2026
(3 years from now) | |
| EP1902029B2 | PF PRISM CV | Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same |
Jun, 2026
(3 years from now) | |
| EP1902029A1 | PF PRISM CV | Crystalline Forms Of 4-[(2,4-Dichloro-5-Methoxyphenyl)Amino]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)Propoxy]-3-Quinolinecarb-Onitrile And Methods Of Preparing The Same |
Jun, 2026
(3 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7919625 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(3 years from now) | |
| US7417148 | PF PRISM CV | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) |
Dec, 2025
(3 years from now) | |
| US11103497 | PF PRISM CV | Treatment of imatinib resistant leukemia |
Feb, 2034
(11 years from now) | |
Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient
Treatment: A method of treating chronic myelogenous leukemia; A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at 949t>c; a method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 100MG BASE | TABLET;ORAL | Prescription |
| EQ 400MG BASE | TABLET;ORAL | Prescription |
| EQ 500MG BASE | TABLET;ORAL | Prescription |
2. Drug name - CHANTIX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6890927 | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
May, 2022
(4 months ago) | |
| US7265119 | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Aug, 2022
(a month ago) | |
| CN1509174A | PF PRISM CV | 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0 |
Apr, 2022
(5 months ago) | |
| CN100370987C | PF PRISM CV | 5, 8, 14-Aminosteroid, Triaza-Tetracyclo [10.3.1.0. 2.11. 0. 4.9]--2 (11), 3, 5, 7, 9, - Pentaene-Tartrate |
Apr, 2022
(5 months ago) | |
| IN200300863P3 | PF PRISM CV | Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| IN204091B | PF PRISM CV | Compound Of 5,8,14-Triazatracyclo[10.3.1.02.11.04.9]-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| EP1392307B1 | PF PRISM CV | Tartrate Salts Of 5,8,14-Triazatetracyclo¬10.3.1.02,11.04,9-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| EP1392307A1 | PF PRISM CV | Tartrate Salts Of 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-Hexadeca-2(11),3,5,7,9-Pentaene |
Apr, 2022
(5 months ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6890927
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Nov, 2022
(a month from now) | |
|
US7265119
(Pediatric) | PF PRISM CV | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Feb, 2023
(4 months from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.5MG BASE | TABLET;ORAL | Prescription |
| EQ 1MG BASE | TABLET;ORAL | Prescription |
3. Drug name - INLYTA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6534524 | PF PRISM CV | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
Apr, 2025
(2 years from now) | |
| US8791140 | PF PRISM CV | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals |
Dec, 2030
(8 years from now) | |
| CN101679356A | PF PRISM CV | Crystalline Form Of 6-[2-(Methyl-Carbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2- Yl)Ethenyl]Indazole Suitable For Treatment Of Abnormal Cell Growth In A Mammal |
Jul, 2014
(8 years ago) | |
| CN1374950A | PF PRISM CV | Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use |
Jun, 2020
(2 years ago) | |
| CN1234693C | PF PRISM CV | Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use |
Jun, 2020
(2 years ago) | |
| CN1137884C | PF PRISM CV | Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods Thereof |
Jun, 2020
(2 years ago) | |
| CN1495171A | PF PRISM CV | Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use |
Jun, 2020
(2 years ago) | |
| CN103626739A | PF PRISM CV | Useful In The Treatment Of Abnormal Cell Growth In A Mammal Of 6 - [2 - (Methyl-Carbamyl) Phenylsulfanyl] -3-E-[2 - (Pyridin - -2 - Yl) Ethenyl] Indazole Of Crystal Form |
Mar, 2028
(5 years from now) | |
| CN103626739B | PF PRISM CV | Suitable Treating Abnormal Cell Growing Mammal Is 6-[2-(Methyl-Carbamoyl) Phenylsulfanyl]-3-E-[2-(Pyridine--2-Yl) Ethenyl] Indazole And Crystal Form |
Mar, 2028
(5 years from now) | |
| EP1614683A1 | PF PRISM CV | Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use |
Jun, 2020
(2 years ago) | |
| EP1614683B1 | PF PRISM CV | Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use |
Jun, 2020
(2 years ago) | |
| EP1218348B1 | PF PRISM CV | Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use |
Jun, 2025
(2 years from now) | |
| EP1218348A2 | PF PRISM CV | Indazole Compounds And Pharmaceutical Compositions For Inhibiting Protein Kinases, And Methods For Their Use |
Jun, 2025
(2 years from now) | |
| EP3252047A3 | PF PRISM CV | Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals |
Mar, 2028
(5 years from now) | |
| EP3252047B1 | PF PRISM CV | Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals |
Mar, 2028
(5 years from now) | |
| EP3252047A2 | PF PRISM CV | Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals |
Mar, 2028
(5 years from now) | |
| EP2134702B1 | PF PRISM CV | Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals |
Mar, 2028
(5 years from now) | |
| EP2134702A2 | PF PRISM CV | Crystalline Forms Of 6-[2-(Methylcarbamoyl)Phenylsulfanyl]-3-E-[2-(Pyridin-2-Yl)Ethenyl]Indazole Suitable For The Treatment Of Abnormal Cell Growth In Mammals |
Mar, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570202 | PF PRISM CV | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
Feb, 2035
(12 years from now) | |
| US10869924 | PF PRISM CV | PD-L1 antagonist combination treatments |
Nov, 2036
(14 years from now) | |
Drugs and Companies using AXITINIB ingredient
Treatment: In combination with pembrolizumab for the first-line treatment of patients with advanced renal cell carcinoma; Axitinib in combination with avelumab for the first-line treatment of patients with advanced renal cell carcinoma
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 1MG | TABLET;ORAL | Prescription |
| 5MG | TABLET;ORAL | Prescription |
4. Drug name - PRISTIQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6673838 | PF PRISM CV | Succinate salt of O-desmethyl-venlafaxine |
Mar, 2022
(6 months ago) | |
| US8269040 | PF PRISM CV | Derivatives of venlafaxine and methods of preparing and using the same |
Jul, 2027
(4 years from now) | |
| CN1501909A | PF PRISM CV | A New O-Demethyl-Venlafaxine Succinate |
Feb, 2022
(7 months ago) | |
| CN100567253C | PF PRISM CV | O-Desmethyl-Venlafaxine Succinate |
Feb, 2022
(7 months ago) | |
| IN200301015P2 | PF PRISM CV | Novel Succinate Salt Of O-Desmethyl-Venlafaxine |
Feb, 2022
(7 months ago) | |
| IN201649B | PF PRISM CV | Novel Succinate Salt Of O-Desmethyl- Venlafaxine |
Feb, 2022
(7 months ago) | |
| EP1466889A1 | PF PRISM CV | O-Desmethylvenlafaxine Succinate |
Mar, 2020
(2 years ago) | |
| EP1466889B1 | PF PRISM CV | O-Desmethylvenlafaxine Succinate |
Mar, 2020
(2 years ago) | |
| EP1360169B2 | PF PRISM CV | Succinate Salt Of O-Desmethyl-Venlafaxine |
Feb, 2022
(7 months ago) | |
| EP1360169B1 | PF PRISM CV | Succinate Salt Of O-Desmethyl-Venlafaxine |
Feb, 2022
(7 months ago) | |
| EP1360169A2 | PF PRISM CV | Succinate Salt Of O-Desmethyl-Venlafaxine |
Feb, 2022
(7 months ago) | |
Drugs and Companies using DESVENLAFAXINE SUCCINATE ingredient
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 25MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 50MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| EQ 100MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
5. Drug name - TORISEL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8299116 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(9 months from now) | |
| US8455539 | PF PRISM CV | CCI-779 concentrate formulations |
Jul, 2023
(9 months from now) | |
| US8722700 | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jul, 2023
(9 months from now) | |
|
US8299116
(Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(1 year, 3 months from now) | |
|
US8722700
(Pediatric) | PF PRISM CV | CCI-779 formulations for parenteral administration |
Jan, 2024
(1 year, 3 months from now) | |
|
US8455539
(Pediatric) | PF PRISM CV | CCI-779 concentrate formulations |
Jan, 2024
(1 year, 3 months from now) | |
| US8026276 | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jan, 2026
(3 years from now) | |
|
US8026276
(Pediatric) | PF PRISM CV | Parenteral CCI-779 formulations containing cosolvents, an antioxidant, and a surfactant |
Jul, 2026
(3 years from now) | |
| US8791097 | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
May, 2032
(9 years from now) | |
|
US8791097
(Pediatric) | PF PRISM CV | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
Nov, 2032
(10 years from now) | |
Drugs and Companies using TEMSIROLIMUS ingredient
Treatment: Method of treating papillary renal cell carcinoma with temsirolimus, in the absence of interferon alpha.; method of treating metastatic papillary renal cell carcinoma with temsirolimus.
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 25MG/ML (25MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
6. Drug name - TYGACIL
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9254328 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(3 years from now) | |
| US10588975 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(3 years from now) | |
| US9694078 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Mar, 2026
(3 years from now) | |
| US8975242 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Oct, 2028
(6 years from now) | |
| US7879828 | PF PRISM CV | Tigecycline compositions and methods of preparation |
Feb, 2029
(6 years from now) | |
| US8372995 | PF PRISM CV | Crystalline solid forms of tigecycline and methods of preparing same |
Oct, 2030
(8 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 50MG/VIAL | POWDER;INTRAVENOUS | Prescription |
7. Drug name - XALKORI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8785632 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Mar, 2025
(2 years from now) | |
| US7230098 | PF PRISM CV | Aminoheteroaryl compounds as protein kinase inhibitors |
Aug, 2025
(2 years from now) | |
| US7858643 | PF PRISM CV | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
Oct, 2029
(7 years from now) | |
| US8217057 | PF PRISM CV | Polymorphs of a c-MET/HGFR inhibitor |
Nov, 2029
(7 years from now) | |
| CN103265477A | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| CN103265477B | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| CN101023064B | PF PRISM CV | As Protein Kinase Inhibitors Of Enantiomer Pure Amino Heteroaryl Compound |
Aug, 2025
(2 years from now) | |
| CN101023064A | PF PRISM CV | The Enantiomer Pure Amino Heteroaryl Compound As Protein Kinase Inhibitor |
Aug, 2025
(2 years from now) | |
| CN101326175A | PF PRISM CV | Polymorphs Of A C-Met/Hgfr Inhibitor |
Nov, 2026
(4 years from now) | |
| CN101326175B | PF PRISM CV | Polymorphs Of A C-Met/Hgfr Inhibitor |
Nov, 2026
(4 years from now) | |
| IN200503734P1 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| IN249316B | PF PRISM CV | An Amino-Pyridine Compound Of Formula I |
Feb, 2024
(1 year, 4 months from now) | |
| IN200700144P1 | PF PRISM CV | Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Aug, 2025
(2 years from now) | |
| IN250050B | PF PRISM CV | An Enantiomerically Pure Aminopyridine Compound Of Formula (I) |
Aug, 2025
(2 years from now) | |
| EP1603570A4 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP1603570B1 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP2476667A3 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP1603570A2 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP1603570B9 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP2476667A2 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP2476667B1 | PF PRISM CV | Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Feb, 2024
(1 year, 4 months from now) | |
| EP1963302A2 | PF PRISM CV | Polymorphs Of A C-Met/Hgfr Inhibitor |
Nov, 2026
(4 years from now) | |
| EP1963302B1 | PF PRISM CV | Polymorphs Of A C-Met/Hgfr Inhibitor |
Nov, 2026
(4 years from now) | |
| EP1786785B9 | PF PRISM CV | Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Oct, 2027
(5 years from now) | |
| EP1786785A2 | PF PRISM CV | Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Oct, 2027
(5 years from now) | |
| EP1786785B1 | PF PRISM CV | Enantiomerically Pure Aminoheteroaryl Compounds As Protein Kinase Inhibitors |
Oct, 2027
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7825137 | PF PRISM CV | Method of treating abnormal cell growth |
May, 2027
(4 years from now) | |
Drugs and Companies using CRIZOTINIB ingredient
Treatment: Treatment of pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (alcl) that is anaplastic lymphoma kinase (alk)-positive; treatment of patients with metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 200MG | CAPSULE;ORAL | Prescription |
| 250MG | CAPSULE;ORAL | Prescription |
8. Drug name - XELJANZ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6965027 | PF PRISM CV | Crystalline 3-{4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3-oxo-propionitrile citrate |
Mar, 2023
(5 months from now) | |
| USRE41783 | PF PRISM CV | Pyrrolo[2,3-D]pyrimidine compounds |
Dec, 2025
(3 years from now) | |
| CN1195755C | PF PRISM CV | Pyrrolo [2, 3-D] Pyrimidine Compound |
Nov, 2020
(1 year, 10 months ago) | |
| CN1409712A | PF PRISM CV | Pyrrolo [2, 3-D] Pyrimidine Compound |
Nov, 2020
(1 year, 10 months ago) | |
| CN1596257A | PF PRISM CV | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| CN1325498C | PF PRISM CV | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| IN200200588P1 | PF PRISM CV | Pyrrolo[2,3-D] Pyrimidine Compounds |
Nov, 2020
(1 year, 10 months ago) | |
| IN241773B | PF PRISM CV | Pyrrolo[2,3-D] Pyrimidine Compounds |
Nov, 2020
(1 year, 10 months ago) | |
| IN200401095P1 | PF PRISM CV | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| IN251800B | PF PRISM CV | 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation |
Nov, 2022
(a month from now) | |
| IN218212B | PF PRISM CV | Crystalline 3-{(3R,4R)-4-Methyl-3-[Methyl-[7H-Pyrrolo[2,3- D]Pyrimidin-4-Yl)-Amino]-Piperidin-L-Yl}-3-Oxo-Propinitrile Mono Citrate Salt And Its Method Of Preparation |
Nov, 2022
(a month from now) | |
| IN200607324P1 | PF PRISM CV | 3-{(3R,4R)-4-Methyl-3-[Methyl-(7H-Pyrrolo[2,3-D]Pyrimidin-4-Yl)-Amino]-Piperidin-1-Yl}-3-Oxo-Propionitrile Mono Citrate Salt And Its Method Of Preparation |
Nov, 2022
(a month from now) | |
| EP1235830B1 | PF PRISM CV | Pyrrolo¬2,3-D Pyrimidine Compounds As Protein Kinases Inhibitors |
Nov, 2020
(1 year, 10 months ago) | |
| EP1235830A2 | PF PRISM CV | Pyrrolo[2,3-D]Pyrimidine Compounds As Protein Kinases Inhibitors |
Nov, 2020
(1 year, 10 months ago) | |
| EP1382339B1 | PF PRISM CV | Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives |
Nov, 2020
(1 year, 10 months ago) | |
| EP1382339A1 | PF PRISM CV | Compositions Containing Pyrrolo ¬2,3-D Pyrimidine Derivatives |
Nov, 2020
(1 year, 10 months ago) | |
| EP1451192A1 | PF PRISM CV | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| EP1451192B1 | PF PRISM CV | Novel Crystalline Compound |
Nov, 2022
(a month from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 5MG BASE | TABLET;ORAL | Prescription |
| EQ 10MG BASE | TABLET;ORAL | Prescription |
9. Drug name - ZMAX
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6984403 | PF PRISM CV | Azithromycin dosage forms with reduced side effects |
Feb, 2024
(1 year, 4 months from now) | |
| US7887844 | PF PRISM CV | Multiparticulate crystalline drug compositions having controlled release profiles |
Feb, 2024
(1 year, 4 months from now) | |
Drugs and Companies using AZITHROMYCIN ingredient
Treatment: Method of treating bacterial infections
Dosage: FOR SUSPENSION, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2GM BASE/BOT | FOR SUSPENSION, EXTENDED RELEASE;ORAL | Discontinued |
availability in other generic markets.
Click on the highlighted region to filter.